The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DOLBI
- 26 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
- 04 Nov 2015 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 04 Nov 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.